R&D trends
Accelerating innovation and its impact on patients and sites
Read More
Search Results for: Eran Gordon
AstraZeneca pleased with quarter despite profits fall
AstraZeneca has posted a 4% decline in second-quarter revenues at constant exchange rates,to $6.23 billion and core operating profit fell 10% to $2.06 billion, hit by patent expiries.
Read MoreEarnings battered but AZ optimistic for future growth
AstraZeneca has posted a 13% decline in first-quarter revenues to $6.39 billion, due to the loss of exclusivity on key brands, but analysts believe things are starting to improve at the Anglo-Swedish drugmaker.
Read MorePulling together: how the UK plans to boost clinical research
“This is a unique moment,” says Sally Davies, director of Research and Development at the Department of Health and Chair of the UK Clinical Research Collaboration.
Read More- Nova’s Xromi approved in UK and EU for vaso-occlusive complications of SCD
- Study reveals vitamin D-altered mouse gut bacteria provides better cancer immunity
- Cambridge researchers use AI to accelerate drug design for Parkinson’s disease
- Study finds mechanical changes in tumour tissue offer new insights for cancer research
- Cambridge study finds AI more accurately assesses eye problems compared to doctors
